The OPTIMA Trial: A Feasibility Study for Genomic Assay-Guided Chemotherapy Decisions
OPTIMA prelim was a successful UK feasibility study that demonstrated the acceptability and practicality of using multiparameter genomic assays to guide chemotherapy decisions in ER-positive, HER2-negative early breast cancer, paving the way for larger validation trials. 1
Trial Design and Population
OPTIMA prelim (Optimal Personalised Treatment of early breast cancer usIng Multiparameter Analysis preliminary study) was designed as a partially blinded randomized controlled trial with adaptive design conducted across 35 UK hospitals between September 2012 and June 2014. 1
Eligible patients included:
- Women aged ≥40 years
- Surgically treated ER-positive, HER2-negative primary breast cancer
- Either 1-9 involved axillary lymph nodes OR node-negative disease with tumor ≥30 mm diameter 1
Study Arms and Intervention
The trial randomized patients between two treatment strategies:
Option 1 (Standard Care): Chemotherapy followed by endocrine therapy
Option 2 (Test-Directed): Oncotype DX testing performed on resected tumor to assign treatment:
- If Recurrence Score (RS) >25: Standard care (chemotherapy + endocrine therapy)
- If RS ≤25: Endocrine therapy alone 1
Patients allocated to chemotherapy remained blinded to their randomization assignment, which is a critical design feature to minimize bias. 1
Primary Endpoints and Success Criteria
The trial had pre-specified feasibility endpoints rather than clinical outcomes:
- Recruit 300 patients within 2 years
- For the final 150 patients specifically:
- Acceptance rate ≥40%
- Recruitment completed within 6 months
- Chemotherapy initiation within 6 weeks of consent in ≥85% of patients 1
Key Findings
The trial successfully met all pre-specified feasibility criteria:
- 350 patients consented and 313 were randomized (exceeding the 300-patient target)
- The final 150 patients were recruited in exactly 6 months
- 92% of patients assigned chemotherapy started treatment within 6 weeks (exceeding the 85% threshold)
- Acceptance rate was 47% among 750 invited patients (exceeding the 40% target) 1
Important quality control finding: 3.7% (12/325) of patients were deemed ineligible on central review of receptor status, highlighting the importance of centralized pathology review. 1
Multiparameter Assay Comparison
A critical component of OPTIMA prelim was comparing multiple genomic assays on 302 tumor samples to select the optimal test for the main trial. The assays evaluated included:
- Oncotype DX
- MammaPrint/BluePrint
- Prosigna (PAM50)
- IHC4 and IHC4 AQUA
- MammaTyper 1
Key observation: While these assays categorized comparable numbers of tumors into low- or high-risk groups, there was only moderate agreement between tests at the individual tumor level (kappa ranges 0.33-0.60 for risk stratification and 0.39-0.55 for molecular subtypes). This finding underscores that different genomic assays are not interchangeable. 1
Economic Analysis
Health economics modeling demonstrated that the value of information to the NHS from further research into multiparameter testing is high, regardless of which test is evaluated. Importantly, Prosigna was identified as the highest priority for further study based on this analysis. 1
Qualitative Research Component
The trial included an integral qualitative recruitment study that provided crucial insights:
- Interviews with researchers and recordings of patient consultations identified recruitment barriers
- Three patient focus groups led to modifications in patient information materials
- These interventions were implemented during the trial to improve recruitment 1
This adaptive approach to addressing recruitment challenges in real-time represents best practice in trial design.
Clinical Implications and Future Directions
OPTIMA prelim achieved its primary aim: demonstrating that a large UK clinical trial of multiparameter assay-based chemotherapy selection in hormone-sensitive early breast cancer is feasible and would be economically worthwhile for the NHS. 1
The success of this feasibility study directly informed the development of OPTIMA-YOUNG, an EU-funded international trial investigating genomic assay-guided chemotherapy de-escalation specifically in premenopausal patients with early-stage HR-positive breast cancer. 2 This extension addresses a critical knowledge gap, as premenopausal women often experience greater treatment burden affecting their physical and psychosocial well-being. 2
Important Caveats
OPTIMA prelim was a feasibility study, not a clinical efficacy trial. It did not provide evidence about whether genomic assay-guided treatment decisions improve patient outcomes compared to standard clinical decision-making. The trial's success means that such evidence can now be generated through appropriately powered randomized controlled trials.
The moderate agreement between different genomic assays highlights that test selection matters—clinicians cannot assume different assays will provide equivalent guidance for individual patients, even if they classify similar proportions of the overall population into risk categories. 1